Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: KDN018
MIFTS: 68

Kidney Disease

Categories: Nephrological diseases, Genetic diseases
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Kidney Disease

About this section

MalaCards integrated aliases for Kidney Disease:

Name: Kidney Disease 12 3 15
Nephropathy 12 76 29 6
Kidney Diseases 43 44 73
Renal Failure 76 55 40
Abnormality of the Kidney 29 6
Kidney Failure 43 73
Renal Failure Adverse Event 73
Abnormal Renal Function 73
Kidney Dysfunction 55
Renal Anomaly 55
Renal Disease 55

Classifications:

MalaCards categories:
Global: Genetic diseases
Anatomical: Nephrological diseases
See all MalaCards categories (disease lists)
ICD10: 33


Sources

Summaries for Kidney Disease

About this section
MedlinePlus : 43 Healthy kidneys clean your blood by removing excess fluid, minerals, and wastes. They also make hormones that keep your bones strong and your blood healthy. But if the kidneys are damaged, they don't work properly. Harmful wastes can build up in your body. Your blood pressure may rise. Your body may retain excess fluid and not make enough red blood cells. This is called kidney failure. If your kidneys fail, you need treatment to replace the work they normally do. The treatment options are dialysis or a kidney transplant. Each treatment has benefits and drawbacks. No matter which treatment you choose, you'll need to make some changes in your life, including how you eat and plan your activities. But with the help of health care providers, family, and friends, most people with kidney failure can lead full and active lives. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Kidney Disease, also known as nephropathy, is related to polycystic kidney disease 4 with or without polycystic liver disease and polycystic kidney disease 1 with or without polycystic liver disease, and has symptoms including polyuria An important gene associated with Kidney Disease is COL4A5 (Collagen Type IV Alpha 5 Chain). The drugs Zinc and Triamterene have been mentioned in the context of this disorder. Affiliated tissues include the kidney, kidney and heart, and related phenotypes are homeostasis/metabolism and cardiovascular system

Disease Ontology : 12 A urinary system disease that is located in the kidney.

Wikipedia : 76 Kidney disease, or renal disease, also known as nephropathy, is damage to or disease of a kidney.... more...

Sources

Related Diseases for Kidney Disease

About this section

Diseases in the Kidney Disease family:

Acute Kidney Failure Chronic Kidney Failure
Renal Infectious Disease Ren-Related Kidney Disease

Diseases related to Kidney Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 648)
# Related Disease Score Top Affiliating Genes
1 polycystic kidney disease 4 with or without polycystic liver disease 35.5 IFT88 PKD1 PKD2 PKDREJ PKHD1
2 polycystic kidney disease 1 with or without polycystic liver disease 35.4 ACE PKD1 PKD2 PKDREJ PKHD1
3 cystic kidney disease 35.4 IFT88 PKD1 PKD2 PKHD1 UMOD
4 polycystic kidney disease 3 with or without polycystic liver disease 35.2 PKD1 PKD2 PKDREJ
5 autosomal dominant polycystic kidney disease 35.2 ACE ALB PKD1 PKD2 PKD2L1 PKDREJ
6 polycystic kidney disease 2 with or without polycystic liver disease 35.2 IFT88 PKD1 PKD1L1 PKD2 PKD2L1 PKDREJ
7 polycystic kidney disease 35.1 IFT88 PKD1 PKD1L1 PKD1L3 PKD2 PKD2L1
8 chronic kidney failure 34.1 ACE ALB B2M COL4A5 CST3 EPO
9 nephronophthisis 33.9 CEP290 PKD1 PKD2 PKHD1 UMOD
10 end stage renal failure 33.4 ACE ALB COL4A5 CST3 EPO PKD1
11 polycystic liver disease 33.3 ALB PKD1 PKD2 PKDREJ PKHD1
12 caroli disease 33.2 PKD1 PKHD1
13 polycystic liver disease 1 with or without kidney cysts 33.1 PKD1 PKD2 PKHD1 UMOD
14 membranous nephropathy 32.7 ACE ALB B2M
15 calciphylaxis 32.6 ALB EPO
16 orofaciodigital syndrome i 32.5 CEP290 IFT88 PKDREJ
17 multicystic dysplastic kidney 32.3 PKD1 PKD2
18 glomerulonephritis 32.1 ALB COL4A4 COL4A5
19 congenital hepatic fibrosis 31.5 PKD1 PKHD1
20 pyelonephritis 31.4 ACE ALB UMOD
21 interstitial nephritis 31.2 ACE ALB UMOD
22 renal hypertension 31.2 ACE ALB EPO
23 uremia 31.1 ALB B2M EPO
24 focal segmental glomerulosclerosis 31.0 ACE ALB COL4A4 COL4A5
25 meckel syndrome, type 1 31.0 CEP290 IFT88 PKDREJ
26 renal dysplasia, cystic 30.9 CEP290 PKD1
27 acute kidney failure 30.8 ALB B2M CST3
28 hypertension, essential 30.7 ACE ALB COL4A5 CST3 PKD1 PKD2
29 urinary tract obstruction 30.6 ALB B2M PKDREJ UMOD
30 urinary system disease 30.3 ACE ALB B2M CST3 EPO PKDREJ
31 epilepsy, progressive myoclonic, 4, with or without renal failure 12.5
32 medullary cystic kidney disease 1 12.4
33 autosomal dominant tubulointerstitial kidney disease 12.4
34 hyperuricemia, pulmonary hypertension, renal failure, and alkalosis syndrome 12.4
35 nephrolithiasis, x-linked recessive, with renal failure 12.3
36 autosomal dominant tubulointerstitial kidney disease, umod-related 12.3
37 medullary cystic kidney disease 2 12.3
38 ventriculomegaly with cystic kidney disease 12.2
39 bifid nose with or without anorectal and renal anomalies 12.2
40 glomerulocystic kidney disease with hyperuricemia and isosthenuria 12.1
41 polycystic kidney disease, infantile severe, with tuberous sclerosis 12.1
42 autoimmune interstitial lung, joint, and kidney disease 12.1
43 mucin-1 kidney disease 12.1
44 polycystic kidney disease 5 12.1
45 autosomal dominant tubulointerstitial kidney disease, muc1-related 12.1
46 ren-related kidney disease 12.0
47 polycystic kidney disease 4 12.0
48 igg4-related kidney disease 11.9
49 autosomal dominant tubulointerstitial kidney disease due to ren mutations 11.9
50 familial juvenile hyperuricaemic nephropathy 11.8

Comorbidity relations with Kidney Disease via Phenotypic Disease Network (PDN): (show top 50) (show all 54)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Acute Myocardial Infarction
Alzheimer Disease Aortic Valve Disease 1
Bladder Neck Obstruction Bronchitis
Bronchopneumonia Cardiac Arrest
Cardiogenic Shock Chronic Kidney Failure
Chronic Myocardial Ischemia Decubitus Ulcer
Deficiency Anemia Diabetic Polyneuropathy
Encephalopathy Esophagitis
Familial Atrial Fibrillation First-Degree Atrioventricular Block
Generalized Atherosclerosis Gout
Heart Disease Hydronephrosis
Hypertension, Essential Hypoglycemia
Hypoglycemic Coma Hypothyroidism
Intermediate Coronary Syndrome Intestinal Obstruction
Iron Deficiency Anemia Ischemic Heart Disease
Malignant Essential Hypertension Microvascular Complications of Diabetes 1
Mitral Valve Disease Nephrosclerosis
Paralytic Ileus Peripheral Vascular Disease
Polycystic Kidney Disease Prostate Cancer
Prostatic Hypertrophy Protein-Energy Malnutrition
Pulmonary Hypertension, Primary, 1 Pyelonephritis
Renal Artery Atheroma Renal Artery Disease
Respiratory Failure Schizophreniform Disorder
Sinoatrial Node Disease Swallowing Disorders

Graphical network of the top 20 diseases related to Kidney Disease:



Diseases related to Kidney Disease
Sources

Symptoms & Phenotypes for Kidney Disease

About this section

UMLS symptoms related to Kidney Disease:


polyuria

MGI Mouse Phenotypes related to Kidney Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.18 PKD1L1 PKD2 UMOD IFT88 CEP290 PKD1
2 cardiovascular system MP:0005385 10.17 PKD1L1 PKD2 PKHD1 CEP290 PKD1 COL4A5
3 immune system MP:0005387 10.02 PKD1 PKD2 PKHD1 UMOD CEP290 COL4A4
4 digestive/alimentary MP:0005381 10.01 PKD1L1 PKD2 PKHD1 PKD1 COL4A4 ALB
5 mortality/aging MP:0010768 9.97 PKD1L1 PKD2 PKHD1 IFT88 CEP290 PKD1
6 liver/biliary system MP:0005370 9.91 PKD2 PKHD1 CEP290 PKD1 ACE ALB
7 renal/urinary system MP:0005367 9.7 PKD1L1 PKD2 PKHD1 UMOD PKD1 COL4A4
8 respiratory system MP:0005388 9.17 PKD1 PKD1L1 PKD2 PKHD1 IFT88 CEP290
Sources

Drugs & Therapeutics for Kidney Disease

About this section

Drugs for Kidney Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1548)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 7440-66-6 23994
2
Triamterene Approved Phase 4,Phase 3,Not Applicable 396-01-0 5546
3
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Not Applicable 137-58-6 3676
4
Spironolactone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1952-01-7, 52-01-7 5833
5
Tazobactam Approved Phase 4,Phase 2,Phase 3,Phase 1 89786-04-9 123630
6
Ticlopidine Approved Phase 4,Phase 3,Phase 2,Phase 1 55142-85-3 5472
7
Etomidate Approved Phase 4,Not Applicable 33125-97-2 36339 667484
8
rituximab Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
9
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
10
Exenatide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 141758-74-9 15991534
11
Clopidogrel Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 120202-66-6, 113665-84-2 60606
12
Hydroxychloroquine Approved Phase 4,Phase 3,Phase 2,Phase 1 118-42-3 3652
13
Cloxacillin Approved, Investigational, Vet_approved Phase 4 61-72-3 6098
14
alemtuzumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 216503-57-0
15
Furosemide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 54-31-9 3440
16
Sulfamethoxazole Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 723-46-6 5329
17
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 111025-46-8 4829
18
Ertapenem Approved, Investigational Phase 4,Phase 2,Early Phase 1 153832-46-3 150610
19
Menthol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2216-51-5 16666
20
Cisplatin Approved Phase 4,Phase 2,Phase 3,Phase 1 15663-27-1 84093 441203 2767
21
Selenium Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7782-49-2
22
Amlodipine Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 88150-42-9 2162
23
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 79902-63-9 54454
24
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 657-24-9 14219 4091
25
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-23-7 5754
26
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 85721-33-1 2764
27
Amiloride Approved Phase 4,Phase 1,Phase 2,Not Applicable 2016-88-8, 2609-46-3 16231
28
Sorafenib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 284461-73-0 216239 406563
29
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 36791-04-5 37542
30
Sevoflurane Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 28523-86-6 5206
31
Warfarin Approved Phase 4,Phase 3,Phase 2,Phase 1 81-81-2 6691 54678486
32
Nafamostat Approved, Investigational Phase 4,Phase 3 81525-10-2
33
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 155213-67-5 392622
34
Losartan Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 114798-26-4 3961
35
Ramipril Approved Phase 4,Phase 3,Phase 2,Not Applicable 87333-19-5 5362129
36
Ursodeoxycholic acid Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 128-13-2 31401
37
Sevelamer Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 52757-95-6
38
Terlipressin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 14636-12-5 72081
39
Deferiprone Approved Phase 4,Phase 3,Phase 2 30652-11-0 2972
40
Ezetimibe Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 163222-33-1 150311
41
Chlorthalidone Approved Phase 4,Phase 3,Phase 2,Not Applicable 77-36-1 2732
42
Midodrine Approved Phase 4,Phase 2,Phase 3,Not Applicable 133163-28-7, 42794-76-3 4195
43
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 2180-92-9, 38396-39-3 2474
44
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-49-6 772 46507594
45
Doxazosin Approved Phase 4,Phase 3,Not Applicable 74191-85-8 3157
46
Clonidine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 4205-90-7 2803
47
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 134678-17-4 60825
48
Procaine Approved, Investigational, Vet_approved Phase 4,Not Applicable 59-46-1 4914
49
Lopinavir Approved Phase 4,Phase 3,Phase 2,Not Applicable 192725-17-0 92727
50
Allopurinol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 315-30-0 2094

Interventional clinical trials:

(show top 50) (show all 9776)
# Name Status NCT ID Phase Drugs
1 Effect of Valsartan vs Perindopril on HOMA-IR Index in Patients With Chronic Kidney Disease Unknown status NCT02299310 Phase 4 Valsartan;Perindopril
2 The Effect and Safety of the Seasonal Trivalent Influenza Vaccine in Chronic Kidney Disease Patients Not on Dialysis Unknown status NCT02105519 Phase 4
3 Folic Acid for Prevention of Contrast Induced Nephropathy Unknown status NCT02444013 Phase 4 Folic acid;Placebo
4 Effects of an Exercise Program in Patients With Hypertensive Chronic Kidney Disease Unknown status NCT01155128 Phase 4
5 Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease Unknown status NCT02231138 Phase 4 Abelmoschus manihot (AM)
6 The Prevention of Contrast Induced Nephropathy by Sarpogrelate in Patients With Chronic Kidney Disease Unknown status NCT01165567 Phase 4 sarpogrelate
7 Preventive Effect of Pitavastatin on Contrast-Induced Nephropathy in Patients With Renal Dysfunction Unknown status NCT01871792 Phase 4 Pitavastatin;Placebo
8 Keto-/Amino Acid Supplemented Low Protein Diet in Patients With Chronic Kidney Disease Unknown status NCT00364884 Phase 4 ketoaminoacid
9 Vitamin K2 and Vessel Calcification in Chronic Kidney Disease Patients Unknown status NCT01101698 Phase 4 Vitamin K2+10μg cholecalciferol;Vitamin D
10 Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy Unknown status NCT02231125 Phase 4 Losartan;Abelmoschus manihot
11 Benidipine and Hydrochlorothiazide in Fosinopril Treated Chronic Kidney Disease Patients With Hypertension Unknown status NCT02646397 Phase 4 Fosinopril;Benidipine;Hydrochlorothiazide
12 Efficacy and Safety of Simvast Controlled Release (CR) and Zocor in Chronic Kidney Disease(CKD) Stage 3, 4 and 5 Patients With Hyperlipidemia Unknown status NCT01564875 Phase 4 Simvast CR;Zocor
13 Opioids in Chronic Kidney Disease Patients Undergoing Hemodialysis Unknown status NCT02452437 Phase 4 Oxycodone
14 Thiazolidinedione (TZD) on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4 Actos (Pioglitazone);Acarbose
15 Effect of Intravenous Acetadote on Incidence of Contrast Induced Nephropathy Unknown status NCT00939913 Phase 4 intravenous NAC;Placebo
16 Sympathetic Nervous System Inhibition for the Treatment of Diabetic Kidney Disease Unknown status NCT01094769 Phase 4 Moxonidine;Placebo
17 Rituximab in Recurrent IgA Nephropathy Unknown status NCT02571842 Phase 4 Intravenous Rituximab;ACEI/ARB and corticosteroids
18 Safety of Add on Aliskiren to Angiotensin Converting Enzyme Inhibitor (ACEI) and Angiotensin I Receptor Blocker (ARB) Treatment in Type 2 Diabetes With Nephropathy Unknown status NCT00949351 Phase 4 Aliskiren 300mg/d
19 N-GAL Allows Intensive Treatment of Contrast Induced Nephropathy Unknown status NCT01491243 Phase 4 Intensive treatment with sodium bicarbonate;Standard treatment with saline infusion
20 Ezetimibe/Simvastatin Combination in Proteinuric Nephropathy Unknown status NCT00861731 Phase 4 simvastatin;EZE/simvastatin;EZE/simvastatin
21 The Canadian Prevention of Renal and Cardiovascular Endpoints Trial Unknown status NCT00231803 Phase 4
22 The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease Unknown status NCT01157260 Phase 4 Kremezin
23 Prevention of Contrast Nephropathy During Diagnostic Coronary Angiogram or PCI With Hydratation Based on LEVDP Unknown status NCT00584350 Phase 4
24 Nutritional Therapy to Prevent Progression of Acute Kidney Injury to Chronic Kidney Disease Unknown status NCT02831062 Phase 4
25 Intravenous Iron in Patients With Anemia of Chronic Kidney Disease Unknown status NCT00204256 Phase 4 Iron sucrose
26 Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy Unknown status NCT02690883 Phase 4 Exenatide;Lispro
27 Aldosterone in Diabetic Nephropathy Unknown status NCT00870402 Phase 4 Spironolactone;Placebo
28 Anti-proteinuric Effect of Calcitriol in Non-diabetic Kidney Disease Patients Unknown status NCT01512862 Phase 4 Calcitriol;Placebo
29 Nephropathy In Type 2 Diabetes and Cardio-renal Events Unknown status NCT00535925 Phase 4 current therapy;irbesartan;ramipril;hydrochlorothiazide;furosemide;amlodipine;atenolol;doxazosin;clonidine;insulin;simvastatin;fibrate;erythropoietin;aspirin
30 Prevention of Contrast-Induced Nephropathy in Diabetic Patients With Undergoing Coronary Angiography Unknown status NCT00950079 Phase 4 Sodium bicarbonate;saline
31 Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy Unknown status NCT01673204 Phase 4 Calcitriol;Placebo
32 Ramipril and Clopidogrel in Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Type 2 Diabetes and Diabetic Nephropathy Unknown status NCT01743014 Phase 4 Ramipril;Clopidogrel
33 Pure Red Cell Aplasia in Patients With Chronic Kidney Disease and in Use of Epoetin Alfa Unknown status NCT02648126 Phase 4
34 Platelet Resistance With Ticagrelor or Standard-Dose Clopidogrel Among CKD and ACS Patients Unknown status NCT02459288 Phase 4 Clopidogrel first;Ticagrelor first
35 Low Protein Diet Supplemented With Ketoanalogs on Reducing Proteinuria and Maintaining Nutritional Status in Type 2 Diabetic Nephropathy Unknown status NCT01300273 Phase 4
36 Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes (SONATA Study) Unknown status NCT01869881 Phase 4 Anplag(Sarpogrelate);Placebo
37 COmparison of the Pharmacodynamics and Pharmacokinetics Ticagrelor Versus Clopidogrel in Patients With CKD and NSTE-ACS Unknown status NCT02578537 Phase 4 Ticagrelor;Clopidogrel
38 Efficacy and Safety of Alprostadil Prevent Contrast Induced Nephropathy Unknown status NCT01722513 Phase 4 Alprostadil ï¹ control
39 Effect of Vitamin D Supplement on Osteoprotegin Expression and Disease Progression in Patients With Chronic Kidney Disease Stage 1 and 2 Unknown status NCT01561222 Phase 4 Calcitriol;placebo
40 Aspirin in the Prevention of Cardiovascular Events in Hemodialysis Patients Unknown status NCT01198379 Phase 4 aspirin;Placebo
41 Enhancing Dialysis Adequacy: Effects of Intradialytic Exercise Unknown status NCT01481688 Phase 4
42 The Change of Urinary Angiotensinogen Excretion After Valsartan Treatment in Patients With Persistent Proteinuria Unknown status NCT00858299 Phase 4 valsartan
43 Reduction or Discontinuation of CNI's With Conversion to Everolimus-Based Immunosuppresion Unknown status NCT00443508 Phase 4 adding Certican to therapy;reducing Tacrolimus
44 Impact of Conversion From Tacrolimus to Sirolimus in African American Renal Transplant Recipients Unknown status NCT00999258 Phase 4 sirolimus
45 Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease Unknown status NCT00235287 Phase 4 Candesartan and enalapril;candesartan and enalapril;candesartan and enalapril;candesartan and enalapril
46 Aliskiren and Muscle Sympathetic Nerve Activity Unknown status NCT00719316 Phase 4 Aliskiren
47 Far Infrared Therapy on AV Fistula Flow, Endothelial Function and Echocardiography in ESRD Patients Unknown status NCT01138254 Phase 4
48 Renal Effects of Meditarranean Diet and Low-protein Diet With Ketoacids on Physiological Intestinal Mibrobiota in CKD Unknown status NCT02302287 Phase 4
49 Revascularization of Renal Artery Stenosis Versus Medical Therapy for the Treatment of Ischemic Nephropathy Unknown status NCT01023373 Phase 4 Medical treatment
50 Marinobufagenin as a Target for DIGIBIND in Hypertensive Patients With End-stage Renal Disease Unknown status NCT00852787 Phase 4 Digoxin immune fab;Placebo

Search NIH Clinical Center for Kidney Disease

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: kidney diseases

Sources

Genetic Tests for Kidney Disease

About this section

Genetic tests related to Kidney Disease:

# Genetic test Affiliating Genes
1 Abnormality of the Kidney 29
2 Nephropathy 29
Sources

Anatomical Context for Kidney Disease

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Kidney Disease:

19
The Kidney

MalaCards organs/tissues related to Kidney Disease:

41
Kidney, Heart, Liver, Bone, Testes, Endothelial, Brain
Sources

Publications for Kidney Disease

About this section

Articles related to Kidney Disease:

(show top 50) (show all 4312)
# Title Authors Year
1
Hepcidin and proinflammatory markers inA children with chronic kidney disease: AA case-control studya8c. ( 29451472 )
2018
2
Obesity Paradox in Advanced Kidney Disease: From Bedside to the Bench. ( 29981348 )
2018
3
Endovascular treatment of cerebral aneurysm after renal transplantation in polycystic kidney disease. ( 29444616 )
2018
4
Cinacalcet versus Placebo for secondary hyperparathyroidism in chronic kidney disease patients: a meta-analysis of randomized controlled trials and trial sequential analysis. ( 29449603 )
2018
5
Hydrophobic pore gates regulate ion permeation in polycystic kidney disease 2 and 2L1 channels. ( 29899465 )
2018
6
No evidence for association between APOL1 kidney disease risk alleles and Human African Trypanosomiasis in two Ugandan populations. ( 29470556 )
2018
7
Does Chronic Kidney Disease-Induced Cognitive Impairment Affect Driving Safety? ( 29977582 )
2018
8
IgG4-related kidney disease: the effects of a Rituximab-based immunosuppressive therapy. ( 29765543 )
2018
9
Ift25 is not a cystic kidney disease gene but is required for early steps of kidney development. ( 29626631 )
2018
10
Recommendations for Diagnostic and Prognostic Evaluation of Autosomal Dominant Polycystic Kidney Disease (ADPKD) with a Focus on Imaging. ( 29382260 )
2018
11
Treatment of Hyperuricemia in Chronic Kidney Disease. ( 29393124 )
2018
12
Hyperuricemia and Progression of Chronic Kidney Disease: Role of Phenotype Transition of Renal Tubular and Endothelial Cells. ( 29393109 )
2018
13
A Novel PKD1 Mutation Associated With Autosomal Dominant Kidney Disease and Cerebral Cavernous Malformation. ( 29887830 )
2018
14
Outcome of autosomal dominant polycystic kidney disease patients on peritoneal dialysis: a national retrospective study based on two French registries (the French Language Peritoneal Dialysis Registry and the French Renal Epidemiology and Information Network). ( 29361078 )
2018
15
Chronic kidney disease and acquired mitochondrial myopathy. ( 29266014 )
2018
16
Practical approaches to the management of autosomal dominant polycystic kidney disease patients in the era of tolvaptan. ( 29423204 )
2018
17
Three Novel Heterozygous COL4A4 Mutations Result in Three Different Collagen Type IV Kidney Disease Phenotypes. ( 29669314 )
2018
18
Tolvaptan in Later-Stage Polycystic Kidney Disease. ( 29394475 )
2018
19
Chronic kidney disease mortality trends in selected Central America countries, 1997-2013: clues to an epidemic of chronic interstitial nephritis of agricultural communities. ( 29437864 )
2018
20
Should kidney volume be used as an indicator of surgical occasion for patients with autosomal dominant polycystic kidney disease? ( 29979446 )
2018
21
A case of congenital left ventricular diverticulum in a patient with autosomal dominant polycystic kidney disease: possible mechanistic link between polycystin and ventricular diverticulum. ( 29876750 )
2018
22
Role of Immune Cells in Diabetic Kidney Disease. ( 29446740 )
2018
23
Differential Clinical Outcomes Between Angiographic Complete Versus Incomplete Coronary Revascularization, According to the Presence of Chronic Kidney Disease in the Drug-Eluting Stent Era. ( 29449272 )
2018
24
Effect of Sirolimus on Native Total Kidney Volume After Transplantation in Patients with Autosomal Dominant Polycystic Kidney Disease: A Randomized Controlled Pilot Study. ( 29880342 )
2018
25
Porphyria and kidney diseases. ( 29644058 )
2018
26
Anti-Transforming Growth Factor I^ IgG Elicits a Dual Effect on Calcium Oxalate Crystallization and Progressive Nephrocalcinosis-Related Chronic Kidney Disease. ( 29651290 )
2018
27
Clinicopathological predictors for progression of chronic kidney disease in nephrosclerosis: a biopsy-based cohort study. ( 29788462 )
2018
28
Inhaling Difluoroethane Computer Cleaner Resulting in Acute Kidney Injury and Chronic Kidney Disease. ( 29977633 )
2018
29
Ectopic Phosphorylated Creb Marks Dedifferentiated Proximal Tubules in Cystic Kidney Disease. ( 29107072 )
2018
30
Predictors of poor neonatal outcomes in prenatally diagnosed multicystic dysplastic kidney disease. ( 29572458 )
2018
31
REPRISE: tolvaptan in advanced polycystic kidney disease. ( 29389391 )
2018
32
Tolvaptan in Later-Stage Polycystic Kidney Disease. ( 29385372 )
2018
33
A case report of remission of refractory membranous nephropathy progressing to stage 4 chronic kidney disease using low-dose rituximab: A long-term follow-up. ( 29924035 )
2018
34
Optimal equation for estimation of glomerular filtration rate in autosomal dominant polycystic kidney disease: influence of tolvaptan. ( 29789986 )
2018
35
Hypomagnesaemia is absent in children with autosomal dominant polycystic kidney disease. ( 29874928 )
2018
36
Autosomal Dominant Polycystic Kidney Disease and Hypertension Masquerading Primary Aldosteronism. ( 29861570 )
2018
37
Cost-Effectiveness of First-Line Sevelamer and Lanthanum versus Calcium-Based Binders for Hyperphosphatemia of Chronic Kidney Disease. ( 29566839 )
2018
38
Prediction of chronic kidney disease after acute kidney injury in ICU patients: study protocol for the PREDICT multicenter prospective observational study. ( 29980878 )
2018
39
3DUS as an alternative to MRI for measuring renal volume in children with autosomal dominant polycystic kidney disease. ( 29306987 )
2018
40
Diagnosis and Treatment of Metabolic Acidosis in Patients with Chronic Kidney Disease - Position Statement of the Working Group of the Polish Society of Nephrology. ( 29895022 )
2018
41
Bilineal inheritance of pathogenic PKD1 and PKD2 variants in a Czech family with autosomal dominant polycystic kidney disease - a case report. ( 29973168 )
2018
42
Hepatitis C virus infection in chronic kidney disease: paradigm shift in management. ( 29961309 )
2018
43
Gadolinium-Based Contrast Agents in Kidney Disease: A Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists. ( 29977584 )
2018
44
Phosphate stimulates myotube atrophy through autophagy activation: evidence of hyperphosphatemia contributing to skeletal muscle wasting in chronic kidney disease. ( 29486729 )
2018
45
Pediatric patient with end-stage kidney disease secondary to Eagle-Barrett syndrome and metastatic unresectable hepatoblastoma treated successfully with chemotherapy and liver-kidney transplant. ( 29356335 )
2018
46
Volume Reduction in Enlarged Kidneys in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Prior to Renal Transplant with Transcatheter Arterial Embolization (TAE): A Systematic Review and Meta-Analysis. ( 29388019 )
2018
47
Autosomal Dominant Tubulointerstitial Kidney Disease: Clinical Presentation of Patients With ADTKD-UMOD and ADTKD-MUC1. ( 29784615 )
2018
48
Effector I^I' T cells in human renal fibrosis and chronic kidney disease. ( 29897565 )
2018
49
Using Machine Learning Algorithms to Predict Risk for Development of Calciphylaxis in Patients with Chronic Kidney Disease. ( 29888059 )
2018
50
No difference in renal injury and fibrosis between wild-type and NOD1/NOD2 double knockout mice with chronic kidney disease induced by ureteral obstruction. ( 29609537 )
2018